Inhibikase Therapeutics, Inc. (IKT): Shareholders' Equity
$172.90M
As of 2025-12-31
$153.33M
As of 2026-06-30
+101.8%
3-year compound annual growth
+77.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $172.90M | +82.3% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $94.87M | +764.2% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $10.98M | -47.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $21.04M | -45.2% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $38.42M | +292.6% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $9.78M | n/a | 2022-03-31, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $172.90M | +82.3% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $27.29M | -79.7% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $122.17M | -51.7% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | -$132.45M | n/m |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $151.49M | +483.4% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $103.87M | -63.8% |
| Aura Biosciences, Inc. (AURA) | 2025-12-31 | $136.91M | -9.9% |
| Cabaletta Bio, Inc. (CABA) | 2025-12-31 | $112.05M | -26.4% |
Compare IKT, VXRT, EDIT, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗